Adenosine in the treatment of stroke: yes, maybe, or absolutely not? - PubMed (original) (raw)
Review
Adenosine in the treatment of stroke: yes, maybe, or absolutely not?
D K von Lubitz. Expert Opin Investig Drugs. 2001 Apr.
Abstract
Agonist stimulation of adenosine A(1) receptors has been consistently shown to result in reduction of brain damage following experimentally induced global and focal brain ischaemia in animals. Unsurprisingly, the use of adenosine A(1) receptors as targets for the development of clinical therapeutics suitable for treatment of ischaemic brain disorders has been suggested by many authors. The latest studies of adenosine and its receptors indicate that adenosine-mediated actions might be far more complex than originally anticipated, casting some doubt about the rapid development of stroke treatment based on adenosine. This review discusses the possible role of adenosine receptor subtypes (A(1), A(2) and A(3)) in the context of their potential as therapeutics in stroke.
Similar articles
- Adenosine and cerebral ischemia: therapeutic future or death of a brave concept?
von Lubitz DK. von Lubitz DK. Eur J Pharmacol. 1999 Apr 23;371(1):85-102. doi: 10.1016/s0014-2999(99)00135-1. Eur J Pharmacol. 1999. PMID: 10355598 Review. - Adenosine and cerebral ischemia: therapeutic future or death of a brave concept?
Von Lubitz DK. Von Lubitz DK. Eur J Pharmacol. 1999 Jan 15;365(1):9-25. doi: 10.1016/s0014-2999(98)00788-2. Eur J Pharmacol. 1999. PMID: 9988118 Corrected and republished. Review. - Right thing at a wrong time? Adenosine A3 receptors and cerebroprotection in stroke.
Von Lubitz DK, Simpson KL, Lin RC. Von Lubitz DK, et al. Ann N Y Acad Sci. 2001 Jun;939:85-96. doi: 10.1111/j.1749-6632.2001.tb03615.x. Ann N Y Acad Sci. 2001. PMID: 11462807 - Unravelling adenosine's effects on stroke.
Fricker J. Fricker J. Mol Med Today. 2000 Feb;6(2):48. doi: 10.1016/s1357-4310(99)01652-4. Mol Med Today. 2000. PMID: 10652476 No abstract available. - Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases.
Abbracchio MP, Cattabeni F. Abbracchio MP, et al. Ann N Y Acad Sci. 1999;890:79-92. doi: 10.1111/j.1749-6632.1999.tb07983.x. Ann N Y Acad Sci. 1999. PMID: 10668415
Cited by
- Adenosine A(1) receptor: Functional receptor-receptor interactions in the brain.
Sichardt K, Nieber K. Sichardt K, et al. Purinergic Signal. 2007 Sep;3(4):285-98. doi: 10.1007/s11302-007-9065-z. Epub 2007 Sep 5. Purinergic Signal. 2007. PMID: 18404442 Free PMC article. - Serum adenosine deaminase activity and acute cerebral infarction: a retrospective case-control study based on 7913 participants.
Ling Y, Jiang C, Xiao Z, Shang X, Li Q, Wang B, Hao M, Liu F, Zhao N, Feng J, Zhao H. Ling Y, et al. Aging (Albany NY). 2022 Oct 17;14(21):8719-8728. doi: 10.18632/aging.204338. Epub 2022 Oct 17. Aging (Albany NY). 2022. PMID: 36260871 Free PMC article. - The role of ATP and adenosine in the brain under normoxic and ischemic conditions.
Pedata F, Melani A, Pugliese AM, Coppi E, Cipriani S, Traini C. Pedata F, et al. Purinergic Signal. 2007 Sep;3(4):299-310. doi: 10.1007/s11302-007-9085-8. Epub 2007 Oct 11. Purinergic Signal. 2007. PMID: 18404443 Free PMC article. - Neuronal Adenosine A2A Receptors Are Critical Mediators of Neurodegeneration Triggered by Convulsions.
Canas PM, Porciúncula LO, Simões AP, Augusto E, Silva HB, Machado NJ, Gonçalves N, Alfaro TM, Gonçalves FQ, Araújo IM, Real JI, Coelho JE, Andrade GM, Almeida RD, Chen JF, Köfalvi A, Agostinho P, Cunha RA. Canas PM, et al. eNeuro. 2018 Dec 26;5(6):ENEURO.0385-18.2018. doi: 10.1523/ENEURO.0385-18.2018. eCollection 2018 Nov-Dec. eNeuro. 2018. PMID: 30627646 Free PMC article. - Progress in the pursuit of therapeutic adenosine receptor antagonists.
Moro S, Gao ZG, Jacobson KA, Spalluto G. Moro S, et al. Med Res Rev. 2006 Mar;26(2):131-59. doi: 10.1002/med.20048. Med Res Rev. 2006. PMID: 16380972 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical